SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong

SINOVAC Biotech Ltd. announced a significant legal victory in Hong Kong, where the High Court denied Advantech/Prime Success's petition for an interim injunction aimed at blocking or delaying the company's US$55.00 per common share special cash dividend, payable around July 7, 2025. This ruling, following a similar defeat for Advantech/Prime in New York, clears another key legal hurdle for the dividend distribution. The court criticized Advantech/Prime for failing to disclose fully and for self-induced urgency, ordering them to compensate SINOVAC, 1Globe Capital, and OrbiMed Partners for legal costs, thereby reinforcing the current SINOVAC board's ability to deliver on its commitment to shareholders amidst ongoing multi-jurisdictional disputes.

Analysis

SINOVAC Biotech (SVA) has secured a significant legal victory against activist shareholder Advantech/Prime, with a Hong Kong court denying a petition for an interim injunction. This ruling is critical as it removes a major legal hurdle for the distribution of a US$55.00 per common share special cash dividend declared by the current board, scheduled for payment around July 7, 2025. The decision follows a similar legal failure for Advantech/Prime in New York, reinforcing the current board's operational control and ability to execute its capital return strategy. The court's rebuke of Advantech/Prime, citing a failure of disclosure and self-induced urgency, along with an order to cover legal costs, lends credibility to the incumbent board's narrative. This event is unfolding within a high-stakes proxy battle, with the board leveraging this win to rally shareholder support for its slate on the WHITE proxy card ahead of a July 8 deadline. The board's communication frames the conflict by contrasting this shareholder-friendly dividend with Advantech/Prime's alleged history of self-serving actions, including a 2020 transaction that resulted in over US$500 million in distributions to the activist while common shareholders received nothing.

Key Decisions for Investors

• The successful legal defense substantially de-risks the payment of the US$55.00 per share special cash dividend, and investors should adjust their valuation models to reflect the increased certainty of this significant capital return.
• With a critical proxy vote deadline on July 8, this court victory materially strengthens the incumbent board's position, and shareholders should consider its direct link to the execution of the dividend when casting their vote.
• Despite this positive ruling, the underlying governance conflict with Advantech/Prime persists, and investors should remain vigilant for further legal or corporate maneuvers that could still pose a risk to the company's stability and capital return plans.